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Abstract
The PI3 kinase/AKT pathway has been shown to increase degradation of the p27 cyclin dependent kinase inhibitor through
phosphorylation of consensus AKT sites on p27 and SKP2, and AKT driven proliferation may be checked by feedback
mechanisms that increase p27 expression and induce senescence. However, these AKT sites are not conserved in mouse,
and it has not been clear whether AKT negatively regulates murine p27. Transgenic mice with a probasin promoter
controlled prostate specific reverse tetracycline transactivator (ARR2Pb-rtTA) were generated and used to achieve
doxycycline inducible expression of a tetracycline operon regulated constitutively active myristoylated AKT1 transgene
(tetO-myrAKT). Doxycycline induction of myrAKT occurred within 1 day and rapidly induced proliferation (within 4 days) and
the development of prostatic intraepithelial neoplasia (PIN) lesions in ventral prostate, which did not progress to prostate
cancer. Cells in these lesions expressed high levels of p27, had increased proliferation, and there was apoptosis of centrally
located cells. Doxycycline withdrawal resulted in apoptosis of cells throughout the lesions and rapid clearing of hyperplastic
glands, confirming in vivo the critical antiapoptotic functions of AKT. Significantly, analyses of prostates immediately after
initiating doxycycline treatment further showed that p27 expression was rapidly increased, coincident with the induction of
myrAKT and prior to the development of hyperplasia and PIN. These findings establish in vivo that murine p27 is not
negatively regulated by AKT and indicate that proliferation in PI3 kinase/AKT pathway driven mouse models is mediated by
p27 independent mechanisms that may be distinct from those in human. Further studies using prostate specific doxycycline
regulated transgene expression may be useful to assess the acute effects of inducing additional transgenes in adult murine
prostate epithelium, and to assess the requirements for continued transgene expression in transgene induced tumors.
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Introduction
PTEN expression is very frequently downregulated through
deletion, mutation or other mechanisms in prostate cancer (PCa),
and Pten loss is common in higher grade primary and advanced
metastatic PCa. Mice with prostate epithelium specific Pten
deletion develop intraepithelial hyperplasia and dysplasia (pros-
tatic intraepithelial neoplasia, PIN), but there is generally a long
latency period before these lesions progress to invasive cancer.
Recent studies indicate that this latency is due to induction of
a p53-dependent senescence pathway, with Pten loss on a p53
deficient background causing a marked acceleration in PCa
development [1,2,3,4].
PTEN loss enhances PI3 kinase signaling and activates its major
downstream effector, AKT. Similar to the effects of Pten loss, mice
with prostate epithelium specific expression of a constitutively
active myristoylated AKT transgene (myrAKT) develop PIN,
although these myrAKT mediated lesions do not progress to
invasive cancer [5]. This may reflect some functional differences
between myrAKT and endogenous AKT that is activated
physiologically downstream of Pten loss, or may reflect additional
AKT independent mechanisms by which Pten loss is driving tumor
progression. In either case, as observed with Pten loss, myrAKT
mediated PIN lesions undergo cellular senescence that is
correlated with high level expression of the cyclin dependent
kinase inhibitor p27 [6]. Significantly, decreased p27 correlates
with more aggressive behavior in human PCa [7], and the
development of PCa in mouse prostate with Pten loss is markedly
accelerated on p27 deficient backgrounds [8]. Similarly, p27
deficient mice expressing myrAKT in prostate epithelium develop
invasive PCa [6], indicating that both p27 and p53 are functioning
to check the progression of PIN to invasive cancer, as had been
reported previously in RB deficient tumor models [9,10].
The Cre mediated loss of Pten and the induction of myrAKT in
these mouse PCa models are controlled by elements from the rat
probasin promoter, which is regulated by androgen and activated
specifically in prostate luminal epithelium [11]. To study the
consequences of acute and chronic oncogene activation and
silencing in adult prostate, this report describes generation of
transgenic mice expressing a reverse tetracycline transactivator
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e41330(rtTA) [12] under the control of elements from the rat probasin
promoter (ARR2Pb) [11], and their use to control expression of
a tetracycline operon regulated myristoylated AKT1 transgene
(tetO-myrAKT) [13].
Results
Doxycycline Mediated Induction of Activated AKT and
PIN in Murine Prostate
Sixteen founder lines transmitting the rtTA transgene were
crossed with a tetO-b-galactosidase reporter strain and prostates
from adult (,8 week) double and control single transgenic mice
treated with doxycycline were examined. Histochemical staining
detected weak b-galactosidase enzyme activity in the ventral
prostate of several lines, with line 42 yielding the strongest and
most consistent staining (data not shown). To determine whether
the rtTA in this line could drive functionally significant levels of
a tetO regulated oncogene, we bred this line with mice containing
a tetO-myrAKT transgene (HA-epitope tagged myrAKT1) [13].
Histological examination of double transgenic mice after 8 weeks
on doxycycline revealed hyperplasia and dysplasia in ventral
prostate (Fig. 1A), with affected glandular acini showing multiple
disorganized layers and cribiforming, intraepithelial lumens,
disrupted cellular polarity, nuclear atypia, apoptotic bodies and
fragment accumulation (Fig. 1B). Anti-BrdU immunostaining of
prostates from mice injected intraperitoneally with BrdU at
4 hours prior to sacrifice confirmed a marked increase in
proliferation (Fig. 1C). In contrast, prostate histology was normal
in doxycycline treated single transgenics and in untreated double
transgenic mice (Fig. 1A).
Immunostaining for the HA-epitope tag on myrAKT showed
that the transgene was expressed specifically in regions showing
hyperplasia (Fig. 1D). There was no detectable HA-staining in the
absence of doxycycline treatment, and no detectable HA-AKT by
immunoblotting (see Fig. 2). Moreover, immunostaining with an
AKT pS473 antibody confirmed that the myrAKT was activated
specifically in these hyperplastic/dysplastic regions. Analysis of
additional animals given doxycycline for 3–5 weeks confirmed that
hyperplasia was induced rapidly (data not shown). As reported
previously in mice with constitutive ARR2Pb driven prostate
epithelial expression of myrAKT [5], we did not observe
progression of these PIN lesions to invasive cancer after
doxycycline treatment for up to 8 months. Although senescence
has been identified as a mechanism preventing progression in PI3
kinase/AKT pathway driven PCa mouse models, we have not yet
seen clear increases in SA-b-galactosidase or HP1 in these PIN
lesions (data not shown). Taken together, these results established
that the ARR2Pb-rtTA transgene could stimulate doxycycline
dependent expression of a tetO-regulated oncogene in prostate
epithelium at functionally significant levels.
Rapid Induction of Apoptosis by Doxycycline Withdrawal
and myrAKT Downregulation
A previous study showed that PIN lesions in mice constitutively
expressing myrAKT in prostate epithelium could be rapidly
reversed by blocking mTOR complex 1 (TORC1) activity through
treatment with a rapamycin analogue [14]. As this treatment does
not selectively block transgene stimulated AKT pathway signaling
and would abrogate basal TORC1 activity, we next determined
whether removing doxycycline had acute effects on established
PIN lesions. A series of double transgenic mice were treated with
doxycycline for 5 weeks and then switched to water without
doxycycline for 0–5 days. Immunoblotting for total AKT, pAKT
and HA confirmed the doxycycline dependent high-level expres-
sion of the AKT transgene, and showed that it was phosphorylated
at both S473 and T308 (Fig. 2A). Expression of the transgene
started to decline by 1 day off doxycycline, and was markedly
decreased by 3–5 days (Fig. 2B). Significantly, there was an
associated rapid histological resolution of hyperplastic lesions, with
the lumens initially filling with cellular debris and clearing by day 5
(Fig. 2C). The rapid decline in AKT activity was confirmed by
immunostaining for pAKT, and by the rapid decline in
phosphorylation of a downstream target, ribosomal protein S6
(Fig. 2D).
Interestingly, staining for cleaved caspase 3 prior to doxycycline
withdrawal indicated that cells undergoing apoptosis were located
primarily in the center of the hyperplastic glands (Fig. 2D). In
contrast, apoptotic cells were readily detected throughout each
gland after doxycycline withdrawal. These findings show that both
suppression of apoptosis and increasing proliferation are critical
functions of AKT in driving hyperplasia, although it may be
contributing to hyperplasia by other mechanisms including
suppression of autophagy or decreasing senescence. The fraction
of cells staining with anti-cleaved caspase 3 is shown in figure 2E,
and cleaved caspase 3 protein also could be detected by
immunoblotting after doxycycline withdrawal (Fig. 2F). The
apoptosis of cells in the center of hyperplastic glands prior to
doxycycline withdrawal, in conjunction with ongoing proliferation
(see Fig. 1C), suggest that apoptosis that is occurring despite high
levels of AKT, in addition to cellular senescence, may be
preventing further progression of these lesions.
AR Protein Expression in vivo is not Downregulated by
Induction of myrAKT
Previous in vitro studies have shown that AKT can phosphor-
ylate serine 213 in the AR N-terminal domain, with subsequent
ubiquitylation by MDM2 and proteasome mediated degradation
[15,16,17,18,19]. However, the effects of AKT on AR expression
appear to be variable and cell line dependent, and whether AR is
a physiological target of AKT in vivo has not been determined.
Therefore, we first examined AR expression by immunohisto-
chemistry in PIN lesions from doxycycline treated double trans-
genic mice versus control mice, and found comparable high level
nuclear expression of AR (Fig. 3A).
To determine whether AR may be downregulated acutely by
activated AKT, we next examined AR expression in prostates after
2–7 days of doxycycline mediated myrAKT induction. Serial
sections after 2 days on doxycycline showed induction of AKT in
scattered luminal epithelial cells, without clear changes in AR
expression (Fig. 3B). A larger fraction of cells expressed activated
AKT after induction for 4 days, but AR expression was again not
clearly decreased in the nuclei of these luminal epithelial cells
located adjacent to the basal cell layer (although modest changes in
AR levels may not be detectable by immunohistochemistry). A
similar pattern was seen after 7 days of doxycycline induction.
Interestingly, AR staining was less intense in many cells with larger
nuclei that were starting to form an additional layer and were not
in direct contact with the basal cell layer (examples indicated by
arrows). These findings indicate that activated AKT does not
directly cause marked changes in AR levels in vivo, but may
indirectly alter AR expression through effects on proliferation or
other pathways.
AKT Induced Proliferation is Independent of p27 Cyclin
Dependent Kinase Inhibitor Downregulation
A major mechanism through which AKT drives proliferation is
phosphorylation and subsequent degradation of the p27 cyclin
Doxycycline Regulated AKT Expression in Prostate
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constitutively expressing an ARR2Pb regulated myrAKT trans-
gene found that p27 was highly expressed in PIN lesions and
contributing to senescence, and that crossing onto a p27 deficient
background resulted in progression to invasive cancer [6]. Studies
in conditional PTEN deficient mice have shown that progression
from PIN to cancer is similarly suppressed by senescence, although
through a p53 dependent pathway [1,2,3]. Nonetheless, p27 is
highly expressed in these PTEN deficient senescent cells, and
crossing onto a p27 deficient background also accelerates their
progression to cancer [8]. These observations have indicated that
PI3 kinase/AKT pathway activation may initially drive pro-
liferation through mechanisms including p27 downregulation, but
that additional mechanisms may subsequently increase p27
expression and result in cellular senescence.
Consistent with these previous studies, we found that p27 was
highly expressed in PIN lesions from mice treated with doxycycline
for ,8 weeks as compared to untreated or normal nontransgenic
mice (Fig. 4A). However, increased p27 was also observed after
doxycycline induction for only 2 weeks, and it was increased in
regions expressing activated AKT without marked hyperplasia
(Fig. 4B). Therefore, to more directly address whether AKT was
initially downregulating p27, and whether a subsequent increase in
p27 may be inhibiting progression of PIN lesions, we examined
induction of myrAKT and p27 expression at very early times after
treatment with doxycycline. As shown in figure 4C, activated AKT
could be detected within 2 days of doxycycline treatment, while
glandular hyperplasia was evident by 4 days. Significantly, p27
expression was not decreased in response to doxycycline, and was
instead rapidly increased relative to adjacent glands that were not
expressing the myrAKT transgene (Fig. 4C). Increased p27 was
observed within 2 days in areas of AKT induction prior to
hyperplasia, and at 4 days was observed in cells that were piling up
into the lumen as well as in cells in contact with the basement
membrane. There were no further clear increases in p27
expression at later time points or in PIN lesions, although the
immunohistochemical staining is not quantitative and does not
exclude further modest increases in p27 in PIN lesions.
AKT Mediated p27 Downregulation in Murine and
Human Cells in vitro is Dependent on T157
Previous studies in human cells, including PCa cells, have shown
that AKT enhances p27 degradation through phosphorylation of
T157, which prevents nuclear translocation and thereby enhances
degradation in the cytoplasm [20,21,22]. Significantly this site is
not conserved in murine p27 (Fig. 5A), although AKT has been
reported to target a distinct site in murine p27 [23]. To determine
whether loss of this T157 site abrogates p27 downregulation in
response to AKT activation in PCa cells, we transfected human
CWR22Rv1 PCa cells [24] (expressing wild-type PTEN) with
a human Flag-tagged wild-type or T157A mutant p27. Cells were
then stimulated with IGF-1 to induce PI3 kinase/AKT activation
and assessed for p27. As expected, IGF-1 stimulation decreased
levels of the endogenous p27 in nontransfected CWR22Rv1 cells
(Fig. 5B). IGF-1 stimulation similarly decreased levels of the
transfected human wild-type p27 (Fig. 5C, representative of three
experiments). In contrast, the T157A mutant was not decreased,
supporting the conclusion that the absence of this site in mouse
abrogates negative regulation by activated AKT.
We next examined a murine PCa cell line, TRAMP-C2, which
was derived from the transgenic SV40 driven TRAMP model
[25]. Consistent with the results in mouse prostate, PI3 kinase/Akt
pathway stimulation by IGF-1 did not decrease p27 protein levels
in these cells (Fig. 5D). To determine whether this was due to
differences in murine versus human p27, we transiently transfected
the TRAMP-C2 cells with the wild-type or T157A mutant human
p27. Significantly, IGF-1 stimulation caused a decline in the wild-
type, but not the mutant p27 (Fig. 5E, data from three experiments
graphed in Fig. 5F). These results further support the conclusion
that p27 is not an AKT substrate in murine prostate epithelium
(Fig. 5D).
Discussion
We initially confirmed that the ARR2Pb-rtTA mice could be
used to rapidly and tightly control expression of the tetO-myrAKT
oncogene. Induction of myrAKT in adult murine prostate
epithelium resulted in PIN lesions that did not progress to invasive
cancer, and the rapid induction of apoptosis and resolution of
these lesions in response to doxycycline withdrawal confirmed that
they remained dependent on the antiapoptotic functions of
activated AKT. These results are consistent with previous data
showing that PIN lesions in ARR2Pb-myrAKT mice respond
rapidly to TORC1 inhibition by a rapamycin analogue [14]. Also
consistent with previous observations, we observed high levels of
p27 expression in established PIN lesions [5,8]. However,
examination of prostates at very early times after doxycycline
induction revealed that p27 expression was already elevated in
histologically normal myrAKT expressing cells and in very early
hyperplastic lesions. We did not observe further increases in p27 in
PIN lesions, but cannot rule out further small increases in PIN
lesions that may contribute to preventing progression to invasive
PCa. Nonetheless, these findings show that AKT driven pro-
liferation in murine prostate epithelium is mediated by mechan-
isms that are independent of AKT mediated p27 downregulation.
AKT has been shown to downregulate nuclear p27 by at least
two mechanisms in human cells. One mechanism is by phosphor-
ylation of a consensus AKT site (T157), which prevents p27
nuclear translocation [20,21,22] and presumably enhances degra-
dation by the cytoplasmic KPC ubiquitin ligase [26] and by the
Skp1/Cullin-1/Skp2 E3 ubiquitin ligase complex that recognizes
p27 subsequent to phosphorylation on T187 by CDK2 [27]. A
second mechanism is by AKT1 mediated phosphorylation of a site
on SKP2 (S72), which decreases its degradation and increases its
cytoplasmic localization [28,29]. Remarkably, these AKT sites on
p27 and SKP2, although conserved in many species including
humans and rats, are not conserved in mice.
While it remains possible that AKT regulates murine p27 and
SKP2 expression directly or indirectly through alternative
mechanisms in some cells or tissues [29], our results indicate that
such alternative mechanisms regulating p27 expression are not
prominent in murine prostate epithelium. Nonetheless, the
marked hyperplasia in response to doxycycline induction of
Figure 1. Doxycycline induces myrAKT expression and development of PIN. (A) Adult double or single transgenic mice were treated as
indicated for 8 weeks and prostates were analyzed for histology. Ventral prostates are shown; no clear alterations were found in dorsal, lateral, or
anterior prostate. (B) Higher power view of PIN lesion is shown. (C) Double transgenic mice induced with doxycycline for 8 weeks were injected
intraperitoneally with BrdU (0.1 ml of 10 mg/ml solution in sterile PBS) at 4 hours prior to sacrifice, and S-phase cells were then assessed by anti-BrdU
immunohistochemistry. Graph show average % of BrdU positive cells counted in 10 high power views (6006) in PIN lesions or in normal glands (NL)
from uninduced control mice. (D) Sequential sections were immunostained for total HA-tagged AKT and phospho-Akt.
doi:10.1371/journal.pone.0041330.g001
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PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e41330Figure 2. PIN lesions are rapidly reversed by doxycycline withdrawal. (A,B) Adult double transgenic mice or WT control mice were
untreated or treated for 5 weeks with doxycycline and pairs of mice were then taken off of doxycycline for 0–5 days and sacrificed. Protein extracted
from half of each ventral prostate was immunoblotted for pAKT (S473 or T308 where indicated), HA, and b-tubulin (loading control). (C) Histology of
representative sections of ventral prostate after 0–5 days of doxycycline withdrawal. (D) Immunostaining of representative ventral prostate sections
for pAKT (S473), pS6, and cleaved caspase-3. (E) Mean % cleaved caspase 3 positive epithelial cells counted in ten random fields from two mice at
each time point. (F) Cleaved caspase 3 immunoblot of proteins extracted from ventral prostate in mice on doxycycline or 1 day after doxycycline
withdrawal.
doi:10.1371/journal.pone.0041330.g002
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be blocking the CDK2 inhibitory function of p27 by novel
mechanisms that remain to be identified. Alternatively, AKT
phosphorylation and downregulation of p21 [30] or high level
induction of D cyclin translation secondary to TORC1 activation
[31] may overcome the inhibition of CDK2 by p27.
Interestingly, a dependence on induction of cyclin D translation
downstream of TORC1 for proliferation in response to AKT
activation in murine prostate epithelium would be consistent with
the dramatic responses to TORC1 inhibition in mouse models
[14], compared to the modest responses seen in humans where
AKT can drive proliferation through p27 downregulation.
Similarly, the inability of AKT to directly target p27 in mouse
prostate may make p53 stimulated expression of p21 a more
potent mechanism for suppressing tumor progression in mouse,
and is consistent with the dramatic acceleration of tumor
formation when Pten is lost on a p53 deficient background [1,2].
Conversely, the ability of AKT to directly target p27 in human
prostate may make it a more potent oncogene that can drive
proliferation despite high level p53 induction of p21, and may in
part explain why p53 loss is relatively uncommon as an early event
in human primary PCa. In any case, these studies demonstrate
a major difference between PI3 kinase/AKT pathway driven
proliferation in human and murine cells that may be relevant for
the interpretation of murine cancer models targeting this pathway
and for the development of therapeutics.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animal studies were approved by the Beth Israel Deaconess
Institutional Animal Care and Use Committee (protocol #107-
2010).
Transgenic Mice and Cell Lines
A SacII-BamHI fragment encoding the rtTA from pUHDrt-
TA2S-M2 [12] was subcloned between the SacII-BamHI sites of
pIRES2-EGFP (Clontech). The XhoI-NotI fragment containing
rtTA-IRES-EGFP was then blunted and cloned into BamHI
digested and blunted pARR2Pb [11] to give the Pb-rtTA-IRES-
EGFP. We confirmed androgen and tetracycline dependent
activity by cotransfection with a tetO-luciferase reporter into AR
expressing PCa cells (data not shown). The Pb-rtTA-IRES-EGFP
fragment was excised for pronuclear microinjection in FVB
(BIDMC Transgenic Facility). Founder lines with detectable
transgene expression by RT-PCR in prostate were initially crossed
with a tetO-b-galactosidase reporter strain. Lines with detectable
b-galactosidase staining then were bred with tetO-myrAKT1
transgenic mice (HA-tagged), which were on a C57Bl/6
background so that the resultant mice were on a mixed FVB
Figure 3. AR expression is not directly modulated in vivo in response to doxycycline induction of activated AKT. (A) AR and pAKT
expression in ventral prostate from double transgenic mice induced or uninduced for 8 weeks. (B) AR and pAKT staining in serial sections of ventral
prostate from double transgenic mice treated with doxycycline for 2, 4, or 7 days. Sections shown are representative of ventral prostates from at least
3 mice at each time. Arrows indicate examples of cells with large nuclei and lower AR that are not in contact with basal layer.
doi:10.1371/journal.pone.0041330.g003
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PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e41330Figure 4. p27 expression is rapidly induced by doxycycline prior to development of PIN. (A) p27 immunostaining in ventral prostate of
double transgenic mice treated for 8 weeks with or without doxycycline, and in prostate from a nontrangenic normal control (higher power). (B) p27
and pAKT expression in double transgenic ventral prostate after 2 weeks of doxycycline. (C) pAKT and p27 expression in ventral prostate of adult
double transgenic mice treated with doxycycline for 2, 4, or 7 days. Sections shown are representative of ventral prostates from at least 3 mice at each
time.
doi:10.1371/journal.pone.0041330.g004
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by doxycycline (1 mg/ml) in the drinking water. To assess
proliferation, mice were injected intraperitoneally with BrdU
(0.1 ml of 10 mg/ml solution in sterile PBS) at 4 hours before
sacrifice. CWR22Rv1 and TRAMP-C2 cells were obtained from
the ATCC (characterization available at ATCC.org) and each
were used within 30 passages (,4 months) of thawing. The
expression vector for p27 (human pcDNA3-Flag-p27 wild-type)
was generously provided by Dr. Masaki Mastsumoto (Kyushu
University, Japan). The pcDNA3-Flag-p27(T157A) plasmid was
constructed from this using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene).
Immunoblotting and Immunohistochemistry
Prostate sections were snap frozen for protein extraction or
formalin fixed. Proteins were extracted in RIPA buffer (50 mM
Tris pH 8.0 with 1% TritonX-100, 0.5% deoxycholate, 0.1%
SDS) and immunoblotted with anti-pAKT pS473 or pT308 (Cell
signaling 193H12 or C31E5E, respectively, at 1:1000 dilutions),
anti-HA (Covance, 1:1000 ), or anti-b-tubulin (Chemicon, 1:2000).
For immunostaining, slides were depariffinized, rehydrated,
heated in boiling 10 mmol/L citrate buffer (pH 6.2) for 30
minutes, and blocked using 5% goat serum. For IHC, primary
antibodies anti-pAKT (pS473, Cell Signaling, 1:200), anti-HA
(Cell Signaling, 1:200 ), anti-pS6 (S240/244, Cell Signaling,
1:2000), anti-cleaved caspase 3 (Cell Signaling, 1:200), anti-p27
(#610242, BD Transduction Laboratories), or anti-AR (1:100,
Upstate) in 1% BSA were incubated overnight at 4uC, followed by
biotinylated secondary antibody and streptavidin-HRP (1:400,
Vector). Slides were developed with 3,3-diaminobenzidine (DAB)
and counterstained with hematoxylin. For IGF-1 stimulation, cells
in 24-well plates were transfected with pcDNA3-Flag-p27(T157A)
or pcDNA3-Flag-p27(WT) using Lipofectamine 2000. IGF-1
(InVitrogen) was added to 10 ng/ml, and cells were lysed in
RIPA buffer with protease inhibitors and 100 mM Na3VO4.
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